Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023627 · ClinicalTrials.gov registry record · Phase 2
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Phase 2 study of Ovarian Cancer, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT07023627 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 160 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT07023627, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Conditions Studied
Interventions
- DRUG INCB123667
Study Locations (20)
Florida
- Florida Cancer Specialists & Research Institute - Fort Myers
- Sylvester Comprehensive Cancer Center - Miami
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Florida Cancer Specialists & Research Institute - West Palm Beach
California
- University of California, Los Angeles Medical Center - Los Angeles
- Scripps Healthscripps Mercy Hospital Prebys Cancer Center - San Diego
Maryland
- Greater Baltimore Medical Center - Baltimore
- John Hopkins University-School of Medicine - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
- Umass Memorial Medical Center, Inc. - Worcester
Alabama
- Usa Health Mitchell Cancer Institute - Mobile
Arkansas
- Uams Winthrop P Rockefeller Cancer Institute - Little Rock
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Georgia
- Northeast Georgia Medical Center Gainesville - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2027-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07023627
The ClinicalTrials.gov registry entry for NCT07023627 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which INCB123667 is the first listed.
NCT07023627 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT07023627 about?
NCT07023627 is a clinical study titled "A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression". This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
What is the current status of trial NCT07023627?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-11-12. Estimated completion is 2027-10-24.
What conditions does trial NCT07023627 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT07023627?
The interventions under investigation include: INCB123667 (DRUG).
Who is sponsoring clinical trial NCT07023627?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07023627 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.